BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 15688368)

  • 1. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
    Dandekar DS; Lopez M; Carey RI; Lokeshwar BL
    Int J Cancer; 2005 Jun; 115(3):484-92. PubMed ID: 15688368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs.
    Dandekar DS; Lokeshwar BL
    Clin Cancer Res; 2004 Dec; 10(23):8037-47. PubMed ID: 15585639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9.
    Ding H; Han C; Zhu J; Chen CS; D'Ambrosio SM
    Int J Cancer; 2005 Feb; 113(5):803-10. PubMed ID: 15499625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celecoxib activates a novel mitochondrial apoptosis signaling pathway.
    Jendrossek V; Handrick R; Belka C
    FASEB J; 2003 Aug; 17(11):1547-9. PubMed ID: 12824303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
    Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
    FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells.
    Kern MA; Schubert D; Sahi D; Schöneweiss MM; Moll I; Haugg AM; Dienes HP; Breuhahn K; Schirmacher P
    Hepatology; 2002 Oct; 36(4 Pt 1):885-94. PubMed ID: 12297835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.
    Fulzele SV; Shaik MS; Chatterjee A; Singh M
    J Pharm Pharmacol; 2006 Mar; 58(3):327-36. PubMed ID: 16536899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
    Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
    Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
    Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
    Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-apoptotic effect of leukotriene D4 involves the prevention of caspase 8 activation and Bid cleavage.
    Wikström K; Juhas M; Sjölander A
    Biochem J; 2003 Apr; 371(Pt 1):115-24. PubMed ID: 12482325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.
    Hsu AL; Ching TT; Wang DS; Song X; Rangnekar VM; Chen CS
    J Biol Chem; 2000 Apr; 275(15):11397-403. PubMed ID: 10753955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
    Liu X; Yue P; Zhou Z; Khuri FR; Sun SY
    J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
    Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.
    Leahy KM; Ornberg RL; Wang Y; Zweifel BS; Koki AT; Masferrer JL
    Cancer Res; 2002 Feb; 62(3):625-31. PubMed ID: 11830509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells.
    Levitt RJ; Pollak M
    Cancer Res; 2002 Dec; 62(24):7372-6. PubMed ID: 12499282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells.
    Song X; Lin HP; Johnson AJ; Tseng PH; Yang YT; Kulp SK; Chen CS
    J Natl Cancer Inst; 2002 Apr; 94(8):585-91. PubMed ID: 11959891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
    Cui W; Yu CH; Hu KQ
    Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
    Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
    Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
    Liu W; Chen Y; Wang W; Keng P; Finkelstein J; Hu D; Liang L; Guo M; Fenton B; Okunieff P; Ding I
    Am J Clin Oncol; 2003 Aug; 26(4):S103-9. PubMed ID: 12902866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.